Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination by Pischedda, Sara et al.
Pischedda et al. Clin Epigenet           (2021) 13:29  
https://doi.org/10.1186/s13148-021-01012-w
RESEARCH
Changes in epigenetic profiles 
throughout early childhood and their 
relationship to the response to pneumococcal 
vaccination
Sara Pischedda1,2,3*† , Daniel O’Connor4*† , Benjamin P. Fairfax5 , Antonio Salas1,3 , 
Federico Martinon‑Torres1,2 , Andrew J. Pollard4  and Johannes Trück4,6* 
Abstract 
Background: Pneumococcal infections are a major cause of morbidity and mortality in young children and immatu‑
rity of the immune system partly underlies poor vaccine responses seen in the young. Emerging evidence suggests 
a key role for epigenetics in the maturation and regulation of the immune system in health and disease. The study 
aimed to investigate epigenetic changes in early life and to understand the relationship between the epigenome and 
antigen‑specific antibody responses to pneumococcal vaccination.
Methods: The epigenetic profiles from 24 healthy children were analyzed at 12 months prior to a booster dose of the 
13‑valent pneumococcal conjugate vaccine (PCV‑13), and at 24 months of age, using the Illumina Methylation 450 K 
assay and assessed for differences over time and between high and low vaccine responders.
Results: Our analysis revealed 721 significantly differentially methylated positions between 12 and 24 months 
(FDR < 0.01), with significant enrichment in pathways involved in the regulation of cell–cell adhesion and T cell activa‑
tion. Comparing high and low vaccine responders, we identified differentially methylated CpG sites (P value < 0.01) 
associated with HLA-DPB1 and IL6.
Conclusion: These data imply that epigenetic changes that occur during early childhood may be associated with 
antigen‑specific antibody responses to pneumococcal vaccines.
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Background
Young children are at higher risk of developing life-
threatening diseases compared with adults, which is 
thought to be due to the immaturity of their immune 
system. They also show reduced immune responses 
to vaccines [1]. Pneumococcal infections are a major 
public health problem worldwide causing high mor-
bidity and mortality in young children who suffer 
pneumonia, meningitis and septicemia, leading up to 
1 million deaths in children under the age of five years 
[2, 3]. Despite many years of research, the specific 
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characteristics of the immune system in early child-
hood that underpins increased susceptibility to infec-
tion has still not been fully elucidated [4]. Furthermore, 
there is great variability in the immune response to vac-
cination in children, with some individuals achieving 
more than 100-fold higher antibody levels post-immu-
nization than others [5, 6]. The reason for this huge 
variation is not understood, and recent studies have 
begun to reveal the genetic determinants of immune 
responses to vaccines [7, 8].
The term epigenetics or ‘the epigenome’ describes 
the summary of heritable changes in expression (i.e., 
function) of genes that are not encoded in the DNA 
sequence and form a mechanism whereby past envi-
ronmental events may be encoded and modify future 
cellular responses. Epigenetic mechanisms have repres-
sive and permissive effects on gene expression and thus 
play a key role in cellular differentiation. DNA meth-
ylation forms the archetypal, heritable, epigenetic mark 
and involves the chemical modification of cytosine and 
cytosine:guanine dinucleotides, resulting in profound, 
typically repressive, effects [9]. DNA methylation pat-
terns can be measured across the whole genome covering 
99% of currently annotated genes in a high-through-
put manner [10]. They differ between individuals, even 
between identical twins, and their change over time is 
influenced by intrauterine and postnatal environmental 
factors such as nutrition, toxins or drugs and illnesses 
[11]. Recent studies have demonstrated that the levels 
of DNA methylation of certain CpG sites are also highly 
correlated with human chronological age [12]. Moreover, 
these DNA methylation features have been proposed as 
a surrogate of the “biological age,” which may actually be 
more relevant than chronological age in predicting age-
related health risks [13]. Different conditions have been 
reported to accelerate age-associated DNA methylation 
profiles such as HIV infection and Down syndrome [14, 
15].
There is increasing evidence demonstrating a key role 
of epigenetics in regulation of human immunity in health 
and disease [16, 17]. Consistent with this, DNA methyla-
tion changes during early childhood have been observed 
in genes implicated in inflammatory processes, encoded 
histone modifiers and chromatin remodeling factors [18]. 
However, the effects of these changes on the immune 
system are unknown. Importantly, there is limited infor-
mation on the relationship between epigenetic changes 
in infancy and the response to vaccination. Here, we 
sought to investigate epigenetic changes in early life in a 
well-studied cohort of healthy children, focusing on the 
characterization of the relationship between epigenetics 
and age in paired samples collected at 12 and 24 months 
of age, and the role of epigenetics on the strength of 
antigen-specific antibody responses to pneumococcal 
vaccination.
Results
Twenty-four children (Table  1) who had received the 
13-valent pneumococcal conjugate vaccine (PCV-13) at 
12 months of age, as part of a previously published clini-
cal trial [19–21], were selected based on their aggregated 
IgG antibody response and categorized into high and 
low responders (Fig. 1 and Additional file 1: Figure 1). Of 
note, this categorization was also valid for post-booster 
serotype-specific opsonophagocytic assay (OPA) titers 
and memory B cells responses (Additional file  1: Fig-
ures  2 and 3), therefore truly grouping individuals into 
high and low vaccine responders. Paired blood samples 
taken at 12 and 24 months of age were assessed by DNA 
epigenetic microarray analysis.
Widespread changes in the epigenome occur between 12 
and 24 months of life
The first step of our analysis focused on the methylation 
changes between the two timepoints (12 vs. 24 months). 
After correcting our linear model for cell-type composi-
tion, we found 721 significant DMPs, associated with 421 
unique genes. Considerable inflation could be observed 
in the QQ plot (Additional file  1: Figure  4), reflecting 
substantial age-related changes to the blood epigenome 
early in life. Of the significant DMPs, 314 (43.6%) were 
hypomethylated with the remaining 407 (56.4%) being 
hypermethylated, in samples collected at 12  months 
of age (Additional file  7: Table  1). The results without 
adjusting for cell compositions are shown in Additional 
file 8: Table 2. There was a clear separation between sam-
ples from 12 and 24 months of age using PCA and hierar-
chical clustering of the 721 DMPs (Fig. 2).
Further analyzing the 721 DMPs, we observed sev-
eral DMRs where multiple adjacent CpGs probes were 
found together showing differential methylation between 
the two different timepoints. For instance, 10 probes 
were associated with nuclear factor I X (NFIX), and 
12 CpGs were observed within the same island region, 
chr6:32118101–32118544, of the proline-rich trans-
membrane protein 1 (PRRT1). Hypomethylated CpGs 
were mainly found in CpG islands, whereas open sea, 
shore and shelf regions were mostly hypermethylated 
(Additional file 5: Figure 5a). Most DMPs were found in 
the gene body, TSS1500 and 5′ UTRs and dominated by 
hypomethylation patterns (Additional file 1: Figure 5b).
We further analyzed DMPs, which showed the high-
est age-dependent differences in methylation by apply-
ing a delta beta (difference in the mean β value of each 
group) threshold of ≥ 0.10. In this way, we detected 24 
DMPs, considered as the DMPs most separating the two 
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age groups (Table 2); of those, 18 CpGs exhibited a higher 
methylation level at 24  months, while the remaining 6 
had a lower methylation pattern at 24 months.
Age‑associated changes in the epigenome are enriched 
for pathways linked to T cell regulation and activation
To investigate which molecular functions or biological 
processes were associated with the DMPs between 12 and 
24 months of age, gene set enrichment analysis was per-
formed. We detected significant enrichment (FDR < 0.05) 
in 151 GO pathways, with the most significant pathways 
being related to regulation of T cell activation, cell–cell 
adhesion and regulation of cytokine production (Fig.  3; 
Additional file 9: Table 3).
Among DMPs, we observed 86 CpGs associated with 
69 unique genes within immune system processes accord-
ing to GO terms. Of these, 53 CpGs showed a decrease 
in methylation with age, while the other 32 exhibited an 
increase in methylation from 12 to 24  months (Fig.  4). 
Some of the genes were represented by multiple DMPs, 
such as HOXB6, NOD2 and LAG3, in the latter we found 
both hypo- and hypermethylated CpGs.
In order to understand if the different responsiveness 
to vaccination was associated with the “biological age” of 
the subjects, we used the epigenetic age estimator devel-
oped by Horvath in 2013 [22] to calculate biological age 
based on methylation patterns. First, we applied age pre-
dictors to the results obtained from samples at the two 
time points and found that chronological and predicted 
biological ages were correlated (Fig.  5a). We did not 
observe significant differences in predicted biological age 
between high and low vaccine responders (Fig. 5b).
Hypomethylation of HLA‑DPB1 and hypermethylation 
of IL‑6 is associated with more robust responses 
to pneumococcal infant vaccination
We next assessed whether differences in antibody 
responses against vaccine antigens were associated with 
methylation patterns by comparing pre-vaccination 
blood epigenome profiles of high responders to those of 
low responders. After applying a FDR < 0.01 correction, 
no statistically significant DMPs were detected. How-
ever, using a less stringent statistical threshold (uncor-
rected P value < 0.01), we found 4067 differentially 
Table 1 Characteristics of study participants
f female, m male
Pneumococcal vaccine 
response
Sex Age at visit 1 (months) Age at visit 3 (months) Ethnicity
High f 12.46 23.82 Indian/British
High f 12.16 23.46 European/White west African
High f 12.43 23.72 White Caucasian/European
High f 12.75 24.05 White Caucasian/European
High f 12.2 23.98 White Caucasian/European
High m 12.72 24.57 White Caucasian/European
High m 11.77 23.52 White Caucasian/European
High m 12.72 24.25 White Caucasian/European
High m 13.28 24.61 White Caucasian/European
High m 12.75 24.28 White Caucasian/European
High m 12.82 24.61 White Caucasian/European
High m 12.85 24.08 White Caucasian/European
Low f 12.56 23.89 White Caucasian/European
Low f 12.49 23.85 White Caucasian/European
Low m 12.39 23.95 White Caucasian/European
Low m 12.16 23.66 Asian South East Asian Heritage
Low m 12.98 24.74 White Caucasian/European
Low m 12.39 23.46 White Caucasian/European
Low m 12.00 23.26 White Caucasian/European
Low m 13.05 24.38 White South African
Low m 12.46 23.49 White Caucasian/European
Low m 12.36 24.21 Canadian/British
Low m 13.18 24.51 White Caucasian/European
Low m 12.92 24.9 White Caucasian/European
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Fig. 1 Study design including sample selection for epigenetic studies and overview of main results
Fig. 2 a Principal component analysis and b heatmap including unsupervised clustering of age (24 vs. 12 months) using the 721 significant 
differentially methylated positions
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methylated CpG sites (Additional file 10: Table 4) asso-
ciated with 2797 unique genes that distinguished high 
from low responders in a PCA (Fig.  6a) and an unsu-
pervised clustering method (Fig.  6b). Similar results 
were obtained for a group comparison at 24  months 
(Additional file 6: Figure 6).
We further investigated among the 4067 DMPs those 
which showed the highest difference in methylation 
between high and low vaccine responders (mean β 
value) and assessed regions containing multiple DMPs 
in genes involved in immune system processes. Among 
the top DMPs identified, there were 4 hypomethyl-
ated positions in high vaccine responders within the 
chr6:33048416–33048814 island region of the HLA 
class II histocompatibility antigen DP(W2) beta chain 
(HLA-DPB1). There were also two CpGs associated 
with interleukin 6 (IL-6) that showed hypermethylation 
in high compared with low vaccine responders (Fig. 6c).
Discussion
In the present study, we demonstrated age-associated 
DNA methylation changes between the first and sec-
ond year of life that were largely related to T cell regula-
tion and activation. In addition, using detailed antibody 
measurements following infant pneumococcal conjugate 
booster vaccination in a clinical vaccine trial, we found 
hypomethylation of HLA-DPB1 and hypermethylation of 
IL6 to be correlated with a stronger response to pneumo-
coccal vaccination.
A total of 721 CpGs were found to be significantly dif-
ferentially methylated between 12 and 24  months of 
age. Multiple DMPs within several DMRs showed simi-
lar methylation patterns suggesting a general epigenetic 
remodeling of these genetic loci. For example, within the 
chr6:32118101–32118544 locus, there were twelve DMPs 
that exhibited a significantly higher methylation pattern 
at 24 compared with 12 months of age. These DMPs are 
Table 2 List of the 24 DMPs with an absolute difference in methylation levels > 0.10 between 12 and 24 months of age
The top 18 CpGs are hypermethylated, while the bottom 6 CpGs are hypomethylated in samples from 24 months compared with 12 months of age
Chr chromosome, *N_Shore/N_Shel North Shore/Shelf, S_Shore/S_Shelf South Shore/Shelf
CpG_ID Chr Position Relation to CGI Gene name Gene group FDR P value Mean value 
(m12–m24)
cg05825244 chr20 2,730,488 Island EBF4 Body 2.96E−04 − 0.2201
cg25556035 chr19 13,127,873 S_Shelf NFIX Body 4.27E−07 − 0.1930
cg14716990 chr10 129,533,731 N_Shore 9.20E−08 − 0.1523
cg22268510 chr6 32,118,420 Island PRRT1 Body 5.14E−07 − 0.1448
cg10767662 chr19 13,127,729 S_Shelf NFIX Body 3.43E−07 − 0.1407
cg01323777 chr17 7,832,943 Island KCNAB3 TSS200 4.09E−05 − 0.1366
cg00254681 chr6 32,118,457 Island PRRT1 Body 1.01E−06 − 0.1321
cg13138089 chr2 233,251,770 Island ECEL1P2 TSS200 7.75E−03 − 0.1309
cg13870494 chr9 72,658,358 N_Shore MAMDC2 TSS200 2.36E−05 − 0.1244
cg20471691 chr17 46,681,316 N_Shelf LOC404266; 
LOC404266; 
HOXB6
Body; body; 5′UTR 4.05E−05 − 0.1164
cg23365801 chr17 7,832,909 Island KCNAB3 TSS200 8.93E−04 − 0.1163
cg23491743 chr2 241,989,271 Island SNED1 Body 2.15E−06 − 0.1141
cg27162435 chr17 7,833,163 Island KCNAB3 TSS1500 8.86E−05 − 0.1099
cg00589520 chr7 23,513,039 N_Shore 1.15E−09 − 0.1053
cg09490371 chr2 233,253,024 Island ECEL1P2 TSS1500 2.54E−03 − 0.1051
cg11617964 chr6 32,118,399 Island PRRT1 Body 1.82E−08 − 0.1027
cg25460807 chr8 21,908,022 S_Shelf 6.25E−04 − 0.1013
cg11041817 chr17 46,685,327 Island HOXB7 Body 4.88E−03 − 0.1011
cg16146033 chr11 62,767,323 OpenSea SLC22A8 Body 5.40E−08 0.1063
cg02481642 chr20 43,343,760 OpenSea WISP2 TSS200 5.78E−06 0.1085
cg25135018 chr1 154,435,948 OpenSea IL6R; IL6R Body; body 1.16E−06 0.1099
cg06688910 chr8 122,466,955 OpenSea 6.72E−08 0.1101
cg17945323 chr11 62,767,406 OpenSea SLC22A8 Body 6.66E−09 0.1103
cg09978533 chr22 46,465,160 N_Shore 9.39E−06 0.1149
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localized within the body of PRRT1 and could poten-
tially alter the expression of PRRT1, as previously dem-
onstrated for other hypermethylated positions in genes 
outside of the promoter area [23]. Little is known about 
the function of PRRT1 although aberrant methylation of 
this gene has been related to neurodevelopmental disor-
ders [24] and to hepatic tumorigenesis [25]. Furthermore, 
we observed a total of 118 CpGs that were previously 
reported to be altered between 3 and 60 months in blood 
leukocytes [18]. In agreement with this previous work, 
we observed 57 CpGs exhibiting an increase in meth-
ylation between 12 and 24 months of age, and 60 CpGs 
showing a decreased methylation with age [18].
Through an enrichment pathway analysis of the age 
dependent DMPs, we observed 86 CpGs that were 
associated with 69 genes involved in several immune 
system processes. Genes that were hypomethylated 
at 24 compared with 12  months included IL12A, previ-
ously shown to be repressed at chromatin level in neo-
natal mononuclear compared with adult cells [26–28], 
as well as BCL10 and NOD2, also previously demon-
strated to decrease methylation with age [18]. In con-
trast, CpGs with an increase in methylation between 12 
and 24  months included genes involved in the regula-
tion of innate immune responses such as tripartite motif 
containing 15 (TRIM15) [30], and the PML Nuclear Body 
Scaffold (PML) [31]. A particular pattern of methylation 
was observed for lymphocyte activating 3 (LAG3), also 
required for T cell regulation [32]. LAG3 was hypo-
methylated at two positions within the chr12:6882855–
6883184 region and hypermethylated in an open sea CpG 
at 24 months, suggesting that diverging methylation pat-
terns may regulate expression of this gene.
There was a clear separation of predicted biological age 
between samples taken at the two study time points. Pre-
dicted biological age was moderately higher than chrono-
logical age, most likely due to the small range of errors 
for whole blood samples that the age predictor exhibits 
[22]. However, predicted biological age was not signifi-
cantly different between high and low vaccine responders 
at any time point suggesting no differences attributable to 
“epigenetic age” between the groups.
The second part of our research study focused on the 
relationship between the epigenome at 12 months of age 
before immunization and the strength of the antigen-
specific IgG response to vaccination. We identified a 
high number of CpGs that separated high from low vac-
cine responders using a less stringent statistical threshold 
(uncorrected P value < 0.01). These CpGs included multi-
ple probes mapping to genes involved in immune system 
Fig. 3 Dot plot of the top 30 GO pathways (FDR < 0.05). Size along the x‑axis indicates the number of genes involved in each pathway. Dot colors 
correspond to the different FDR P values associated with the pathways
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processes and were associated with large differences 
in methylation between the two groups. In this way, we 
observed two particularly interesting immune genes 
(HLA-DPB1 and IL6) that contained multiple DMPs dif-
fering between high and low vaccine responders. Hypo-
methylation of HLA-DPB1 as found in high compared 
with low vaccine responders may indeed strengthen the 
overall immune response as previously demonstrated 
by the contribution of HLA to cellular host immunity 
in response to anthrax vaccine adsorbed [33]; rubella 
vaccine [34]; hepatitis B vaccine; and the inactivated 
Japanese encephalitis vaccine [35]. Additional evidence 
connecting HLA genotype and expression to vaccine 
immune responses was found in measles seropositive and 
seronegative individuals [36]. Two CpGs in the body of 
IL6 showed higher methylation in high compared with 
low vaccine responders. These CpGs in open sea posi-
tions (i.e., isolated in the genome [37]) are considered 
to be “predicted enhancer elements” [38], therefore pos-
sibly impacting IL6 expression. Il-6 is a proinflamma-
tory cytokine involved in a variety of immune processes 
and also plays an important role in mediating innate and 
adaptive immune responses [39]; therefore, differential 
expression of IL6 may impact vaccine immune responses. 
However, in contrast to our finding of hypermethylated 
(and possibly reduced expression of ) IL6 in high vaccine 
responders, previous work suggested that IL-6 promotes 
stimulation of humoral and cellular immune responses 
[40–43].
There are several limitations to our study. First, sev-
eral samples had to be excluded due to unavailability of 
genetic material, consent for genetic analysis or miss-
ing serum, which may have affected the results. In addi-
tion, high and low responders were categorized using 
the aggregated serotype-specific IgG response 1-month 
post-booster vaccination, which may not accurately 
Fig. 4 Thirty of the most significant DMPs associated with immune genes grouped according to their GO function. The y‑axis represents the 
β‑value for each position (purple for 12 months, green for 24 months). Red squares indicate CpGs with hypermethylation at 24 compared with 
12 months samples, while for the remaining CPGs, hypomethylation was found at 24 compared with 12 months of age
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reflect the strength of the overall immune response to 
immunization. Reassuringly, however, high vaccine 
responders showed similar patterns in OPA and mem-
ory B-cell responses, indicating that this categorization 
also seems to hold up in different measurements of the 
immune response.
Conclusion
In the present study, we have studied changes in meth-
ylation patterns of healthy children between 12 and 
24 months of age and found that these involved regions 
dominated by immune pathways such as T cell regu-
lation and activation. In addition, we found a number 
of CpGs associated with the strength of the antigen-
specific IgG antibody response to a pneumococcal 
conjugate booster vaccine including differences in 
methylation patterns in HLA-DPB1 and IL6. These lat-
ter findings suggest that epigenetic patterns may influ-
ence antibody responses in young children and may 
potentially add to their susceptibility to infection.
Methods
Study subjects and sample selection
In a previous clinical trial, 178 children were rand-
omized to receive a booster dose of either the 10- or the 
13-valent pneumococcal conjugate vaccine (PCV-13) at 
12  months of age following receipt of PCV-13 at 2 and 
4 months of age [19–21]. Ethical approval for this clinical 
vaccine trial was obtained from the Oxfordshire Research 
Ethics Committee (Reference number 11/SC/0473). Ethi-
cal permission to store and study genetic material was 
obtained prior to enrolment into the study, in accordance 
with the Oxford Vaccine Centre Biobank (10/H0504/25). 
Detailed immune responses were measured before and 
at 1 and 12 months after the booster. At the three study 
time points, anti-polysaccharide serum Immunoglobulin 
G (IgG) and opsonophagocytic assay (OPA) titers to all 
PCV-13 serotypes were determined, and antigen-specific 
memory B cell responses were measured for selected 
pneumococcal polysaccharides. For the purpose of this 
study, 24 individuals who had received a PCV-13 booster 
dose at 12 months of age (n = 90) (baseline group) were 
Fig. 5 a Correlation between chronological (x axis) and predicted biological age (y axis) as calculated with the Horvath epigenetic age estimator. b 
Comparison of predicted biological age between high‑ and low‑responders at the two study time points
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selected based on their aggregated IgG antibody response 
and categorized into high and low responders. For this 
categorization, the strength of the polysaccharide-spe-
cific IgG response was ranked for each PCV-13 recipient 
and vaccine serotype at 1  month following the booster. 
The overall IgG antibody response was then calculated 
by determining the median rank for all serotypes. After 
excluding participants with missing serum or DNA sam-
ples, 38 individuals remained, of whom the 12 high and 
12 low responders were selected (Fig.  1). This categori-
zation was also valid for post-booster serotype-specific 
OPA and memory B cells responses. We used Infinium 
Methylation 450 K to profile (1) the epigenetic differences 
between two timepoints: 12  months (baseline group) 
and 24 months and (2) to elucidate the methylation dif-
ferences between high and low PCV-13 booster vaccine 
responders, in order to identify pathways that show sig-
nificant changes over time and those that are associated 
with a more robust immune response.
Laboratory procedures
Polysaccharide-specific antibody measurements were 
performed as previously described [19, 44]. DNA was 
extracted from blood clots collected from the same par-
ticipants at 12 and 24 months of age. Whole blood DNA 
was bisulfite converted using the EZ-96 DNA Bisulfite 
Fig. 6 a Principal components analysis and b unsupervised clustering with heatmap of 4067 differentially methylated CpG sites (uncorrected P 
value < 0.01) at 12 months of age and grouping by high and low vaccine responders. c Boxplots showing 4 DMPs associated with hypomethylation 
of HLA-DPB1 and 2 DMPs associated with hypermethylation of IL6 in high vaccine responders. The y‑axis represents the β value for each position in 
both groups (yellow for high responders, light blue for low responders)
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Zymo Research conversion protocol according to the 
manufacturer’s instructions. The treated DNA was then 
hybridized to the Illumina Infinium Methylation450K 
BeadChip, and the array was imaged using the Illumina 
iScan system in which the percent methylation state of 
each CpG site was quantified for the entire study group.
Data analysis
The epigenetic profile from study participants was meas-
ured at both time points using the Illumina Methylation 
450  K assay covering > 485,000 methylation sites per 
sample at single-nucleotide resolution. DNA methylation 
analyses were conducted using R software (v.3.6.1) and 
several Bioconductor packages. Raw intensity files were 
preprocessed and transformed into β and M values using 
the R package minfi. The intensities of β values were esti-
mated from the intensity ratio of the methylated signals 
over the total (methylated and unmethylated) signals for 
each site that represents the percentage of methylation at 
a given cytosine for an individual across the blood cells. 
The β value ranges between 0 (position not methylated 
in any of the cells) and 1 (position methylated in all cells 
in the sample). The M value instead is defined as the log2 
ratio of the intensities of methylated vs. unmethylated 
probes and indicates hypermethylation (if positive) and 
hypomethylation (if negative). M values close to 0 repre-
sent a similar intensity between methylated and unmeth-
ylated probes.
All raw data passed quality control and normalized 
using the function preprocessQuantile of the minfi pack-
age. Subsequently, to avoid artifactual data, probes with 
a detection P value > 0.01, probes located in sex chromo-
somes, probes in sites containing SNPs or with a minor 
allele frequency < 5% and probes known to have cross-
reaction were removed. This filtering removed 28,999 
leaving 456,513 probes for subsequent analysis. As the 
DNA samples were obtained from peripheral blood 
and because of the extreme cell-type specificity of DNA 
methylation [45], cell composition heterogeneity was 
evaluated [46] using the package FlowSorted.Blood.450 K 
and the estimateCellCounts function. Batch effect was 
removed using Combat from SVA package.
Identification of differentially methylated probes/posi-
tions (DMPs) between the study timepoint and high- 
and low-responders to the vaccine was performed using 
limma package [47] fitting a linear regression model to 
each CpGs site. M-values are more homoscedastic than 
β-values and were thus used for all statistical analyses 
because of their better detection sensitivity [48]. How-
ever, we report β-values in text and figures to facilitate 
interpretation. Through limma package, it was possible 
to include covariates in the specification of the model (M 
values ~ Group + Individuals + Responder + Sex + Cell 
Composition). Output of the linear model was further 
analyzed using an empirical Bayes method to moder-
ate standard errors. P values were corrected for multiple 
testing using the Benjamini–Hochberg false discovery 
rate (FDR) method [49], and DMPs were defined as all 
positions with an FDR P value < 0.01. CpGs were anno-
tated using Bioconductor package lluminaHumanMeth-
ylation450kanno.ilmn12.hg19 (v1.2) to genomic regions 
classified in regions 200 bp upstream of the transcription 
start site (TSS; TSS200), 1500  bp upstream of the TSS 
(TSS1500), the 5′ and 3′ untranslated regions (UTRs), 
 1st exon and gene body. Regions are further subdivided 
according to their relation to CpG-rich DNA sequences, 
the so-called CpG islands (CGI), in CpG N or S shelves 
(within ~ 4  kb north or south from CGI), CpG N or S 
shores (within ~ 2 kb north or south from CGI) and open 
sea (region > 4  kb from CGI). Differentially methylated 
regions (DMRs) refer to genomic regions with multiple 
differentially methylated positions close together and 
with different methylation patterns across samples.
Principal component analysis (PCA) was performed to 
visualize global epigenome patterns comparing 12- and 
24-month samples as well as samples from high and low 
responders. Pathway analysis was performed employing 
the methylglm function of the methylGSA package [50]. 
This function adjusts for the number of CpGs by imple-
menting a logistic regression model using a functional 
class scoring method; all CpGs ranked by differential 
methylation test P values were considered in gene set 
testing since each CpGs could be of interest. Pathways 
enrichment was considered significant if false discovery 
rate (FDR) < 0.05.
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